PAH drug LTP001 safety study ends early – limited data available

NCT ID NCT05764265

Terminated Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at the long-term safety of the drug LTP001 in people with pulmonary arterial hypertension (PAH), a serious lung condition. It was an open-label extension for patients who had completed a previous study. However, the study was terminated early, and no one reached the full 52 weeks of treatment. Only 31 people took part, and final safety checks were done at the end of treatment instead.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LTP001 (a drug taken orally once daily)
What this could lead to: If successful, this could show that LTP001 is safe and effective for long-term use in managing pulmonary arterial hypertension.
What could go wrong: The study was terminated early with only 31 participants, so results are limited. No patients completed the full 52 weeks, making it hard to draw firm conclusions about long-term safety or benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary arterial hypertension pulmonary hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PULMONARY ARTERIAL HYPERTENSION

Contacts and locations

Locations

Novartis Investigative Site

Caba, Buenos Aires, C1025ABI, Argentina
Novartis Investigative Site

Dresden, Saxony, 01307, Germany
Novartis Investigative Site

Heidelberg, 69120, Germany
Novartis Investigative Site

Amsterdam, North Holland, 1081 HV, Netherlands
Novartis Investigative Site

Krakow, 31 202, Poland
Novartis Investigative Site

Lodz, 91-347, Poland
Novartis Investigative Site

Wroclaw, 50-556, Poland
Novartis Investigative Site

Barcelona, 08036, Spain
Novartis Investigative Site

Madrid, 28041, Spain
Novartis Investigative Site

Málaga, 29010, Spain
Novartis Investigative Site

Sheffield, South Yorkshire, S10 2JF, United Kingdom
Pulmonary Associates PA

Mesa, Arizona, 85206, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.